A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months (START)

Abstract The START study is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo for approximately 18 months (72 weeks) in approximately 540 participants diagnosed with early Alzheimer’s disease (AD). This study is a public-private partnership with shared leadership responsibility across the Alzheimer’s Clinical Trial Consortium (ACTC) and Cognition Therapeutics, Inc.